Mark J. Ratain to Evidence-Based Medicine
This is a "connection" page, showing publications Mark J. Ratain has written about Evidence-Based Medicine.
Connection Strength
0.294
-
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. Cancer Res. 2012 Oct 15; 72(20):5145-9; discussion 5150.
Score: 0.085
-
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
Score: 0.079
-
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55.
Score: 0.066
-
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711.
Score: 0.040
-
Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther. 2014 Apr; 95(4):361-4.
Score: 0.024